Transitioning From Thrombopoietin Agonists to the Novel SYK Inhibitor Fostamatinib: A Multicenter, Real-World Case Series
David M. Hughes,(1) PharmD, BCOP, Charina Toste,(2) DNP, APN, Christopher Nelson,(3) ACNP-BC, Juliet Escalon,(4) ANP, Frances Blevins,(5) PA-C, and Bhavesh Shah,(1) RPh, BCOP
From (1)Department of Pharmacy, Boston Medical Center, Boston, Massachusetts; (2)OptumCare Cancer Clinic, Las Vegas, Nevada; (3)Avera Medical Group Oncology & Hematology, Aberdeen, South Dakota; (4)Mount Sinai Health System, New York, New York; (5)Department of Medicine, Boston University, Boston, Massachusetts
Authors’ disclosures of conflicts of interest are found at the end of this article.
Correspondence to: David Hughes, PharmD, BCOP, 830 Harrison Avenue, Boston, MA 02118. E-mail: email@example.com
J Adv Pract Oncol 2021;12(5):508–517 |
© 2021 Harborside™
Fostamatinib is an oral spleen tyrosine kinase (SYK) inhibitor used for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Clinical and operational barriers may exist that warrant bridging or switching from thrombopoietin receptor agonists (TPO-RAs), such as volatility or unpredictability of platelets, adverse events, and quality of life or patient preference. While fostamatinib demonstrated durable platelet responses, the safety and efficacy in combination, bridging, and/or switching with TPO-RAs is not well documented. The objective of this article is to provide guidance from real-world case studies for a safe and effective strategy for the transitioning of patients from TPO-RAs to fostamatinib, with some degree of overlap between the two agents. Currently, the evidence does not exist to guide the safe and effective use of combination therapy or transition between therapies in ITP. This case series highlights the importance to further understand the complexities of managing this disease, as well as successfully combining, bridging, and/or switching patients over to fostamatinib without the need for rescue therapy or increase in adverse events. The need for real-world evidence that guides providers on the safety and efficacy of short- and long-term combination therapy of fostamatinib and TPO-RAs is crucial. The rationale for combination therapy is to target different pathways, platelet destruction, and production without added toxicities. Additionally, gradual tapering off of TPO-RAs may provide a more favorable clinical outcome when switching to fostamatinib. The need for additional data is necessary to provide clinicians with guidance when managing patients with ITP.
For access to the full length article, please sign in